Chong Kun Dang Enrolls First U.S. Patient in Global Phase 1/2a Trial of ADC Cancer Drug CKD-703
核心洞察
Chong Kun Dang (搜索) has enrolled the first U.S. patient in a global Phase 1/2a clinical trial of CKD-703, an antibody-drug conjugate targeting c-MET (搜索) for cancer (搜索) treatment.
The trial will be conducted at approximately 12 institutions in Korea and the United States, including MD Anderson Cancer Center, targeting patients with non-small cell lung cancer (搜索) and various solid tumors (搜索).
CKD-703 represents a next-generation ADC platform technology applied to a proprietary monoclonal antibody targeting the hepatocyte growth factor receptor (搜索) developed by Chong Kun Dang (搜索).
South Korean pharmaceutical company Chong Kun Dang (搜索) has achieved a significant milestone by enrolling the first U.S. patient in its global Phase 1/2a clinical trial of CKD-703, an antibody-drug conjugate (ADC) cancer (搜索) drug candidate. The enrollment took place at the Gabrail Cancer Center (搜索) in Ohio, marking the beginning of international expansion for this next-generation cancer therapy.
Trial Design and Scope
The global clinical trial will be conducted at approximately 12 institutions across Korea and the United States, including the prestigious MD Anderson Cancer Center. The study targets patients with non-small cell lung cancer (搜索) (NSCLC) and various solid tumors (搜索), representing a broad approach to cancer (搜索) treatment with this novel ADC platform.
The primary objectives of the Phase 1/2a trial are to assess the safety profile of CKD-703, determine the maximum tolerated dose (MTD), and establish the optimal dosing regimen based on proof of concept (PoC) data. This dose-escalation study design is typical for first-in-human trials of novel cancer (搜索) therapeutics.
Innovative ADC Technology
CKD-703 represents an innovative approach to cancer (搜索) treatment, combining Chong Kun Dang (搜索)'s proprietary monoclonal antibody technology with next-generation ADC platform capabilities. The drug candidate targets the hepatocyte growth factor receptor (搜索) (c-MET (搜索)), a well-established oncology target associated with tumor growth, invasion, and metastasis.
According to the company, CKD-703 is designed as an innovative drug candidate that "selectively kills only cancer (搜索) cells," highlighting the precision medicine approach inherent in ADC technology. This selectivity is achieved through the targeted delivery of cytotoxic payloads directly to cancer cells expressing the c-MET (搜索) receptor.
Regulatory Milestones and Timeline
The development of CKD-703 has progressed through several key regulatory approvals. The U.S. Food and Drug Administration (FDA) granted approval for the Phase 1/2a clinical trial in July 2023, followed by investigational new drug (IND) approval from Korea's Ministry of Food and Drug Safety (搜索) in February 2024.
Patient enrollment began in the first half of 2024, with the company planning to expand the trial to additional countries, including those in Europe. This international expansion strategy reflects the global potential the company sees for CKD-703 in addressing unmet medical needs in oncology.
Strategic Implications
A Chong Kun Dang (搜索) official emphasized the significance of this milestone, stating, "This first patient enrollment in the United States signifies that the global clinical trial of CKD-703, our next-generation flagship pipeline, is progressing smoothly." The company views this development as validation of its approach combining proprietary antibody technology with established ADC platforms.
The company has positioned CKD-703 as a potential best-in-class cancer (搜索) drug, with ambitions to "provide innovative treatment options to patients around the world." This positioning reflects the competitive landscape in ADC development, where multiple companies are racing to develop more effective and safer antibody-drug conjugates.
The successful initiation of U.S. patient enrollment represents a critical step in CKD-703's development pathway, bringing the company closer to generating the clinical data needed to support potential regulatory submissions and partnerships in the global oncology market.